Announcement • Aug 14
Biomea Fusion Doses First Patient in Opal Study Evaluating Icovamenib in Combination with Semaglutide in Obesity Biomea Fusion, Inc. announced that the first participant has been dosed in a new arm of the ongoing platform research study, Investigating and Optimizing Physical Function with Weight Loss: A Multi-Arm Open Label Adaptive Platform Trial (OPAL). The study is being conducted in collaboration with the University of Leicester and is led by Professor Dame Melanie Davies and Professor Thomas Yates at the University of Leicester and Leicester Diabetes Centre (LDC) and the NIHR Biomedical Research Centre Leicester. The newly activated experimental OPAL study arm will evaluate the effects of Biomea’s investigational small molecule, icovamenib (100mg, QD for 12 weeks) in combination with low-dose semaglutide (for 24 weeks) versus low dose semaglutide alone (for 24 weeks) in individuals without type 2 diabetes that are either overweight (with one or more weight-related complications) or obese. This randomized double-blind study-arm, is designed to enroll 64 participants randomized 1:1 to assess whether adding icovamenib to semaglutide can enhance weight loss while evaluating its potential effects on physical function, body composition, muscle health, and metabolic outcomes. The primary endpoint assessment will be performed at Week 24. The clinical evaluation of icovamenib in combination with semaglutide is supported by preclinical studies in which icovamenib enhanced the efficacy of semaglutide, with improved weight reduction driven by fat loss and observed preservation of lean mass. Additional preclinical studies have demonstrated that icovamenib upregulates GLP-1 expression, supports myogenesis, and shifts adipose tissue metabolism toward energy expenditure. Together, these findings support the evaluation of icovamenib in combination with GLP-1 receptor agonist-based therapy as a potential approach to improve weight loss while supporting broader metabolic health. Icovamenib is an orally administered investigational small molecule currently in Phase 2 clinical development for the treatment of type 1 and type 2 diabetes. Preclinical evidence shows that icovamenib promotes reversible downmodulation of menin, a transcriptional regulator implicated in beta cell biology. Preclinical data also has shown that icovamenib induced glucose-dependent beta cell proliferation and enhances insulin production and secretion. Through these proposed mechanisms, icovamenib has the potential to restore beta cell mass and function and thereby improve glycemic control. As a potential beta cell restorative therapy, icovamenib represents a novel treatment approach for individuals living with diabetes. Price Target Changed • May 22
Price target decreased by 9.7% to US$6.83 Down from US$7.57, the current price target is an average from 6 analysts. New target price is 381% above last closing price of US$1.42. Stock is down 4.1% over the past year. The company is forecast to post a net loss per share of US$0.81 next year compared to a net loss per share of US$1.18 last year. New Risk • May 01
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$98.3m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$70m free cash flow). Earnings are forecast to decline by an average of 9.2% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (92% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$104m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$98.3m market cap). 
